Ireland-based Perrigo has signed an agreement with GlaxoSmithKline Consumer Healthcare (GSK) to acquire its portfolio of over-the-counter (OTC) brands.

Perrigo will purchase the OTC portfolio in an all-cash transaction, although financial details of the deal have not been disclosed.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

GSK has divested the brands because the company had committed to sell these brands to form a consumer health joint venture between the firm and Novartis International.

"We are building on the global platform we established with the Omega Pharma acquisition to capture an even greater share of the $30bn European OTC market opportunity."

Perrigo chairman, president and CEO Joseph Papa said: "This acquisition demonstrates Perrigo’s ability to execute on our ‘Base Plus Plus Plus’ strategy, in which we make selective, accretive transactions to expand our durable base business.

"We are building on the global platform we established with the Omega Pharma acquisition to capture an even greater share of the $30bn European OTC market opportunity with several well-established, complementary brands that bolster our OTC product portfolio."

See Also:

Under the deal, Perrigo will acquire GSK’s NiQuitin nicotine replacement therapy (NRT) business in the European Economic Area (EEA) and Brazil, as well as Novartis’s Australian NRT business, including the Nicotinell brand.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Perrigo will also acquire OTC brands such as Coldrex (cold and flu treatment) across the EEA and Panodil (pain relief), Nezeril (nasal decongestant), and Nasin (nasal decongestant) in Sweden.

In addition, the deal will allow Perrigo to acquire Novartis’s legacy cold sore management product in the EEA, which are marketed under the brand names Vectavir, Pencivir, Fenivir, Fenlips, and Vectatone.

The brands being acquired reported net sales of around $110m in 2014.

Subject to customary closing conditions, the deal is expected to be completed in the third quarter of this year.